aluates Reports

$ 0.0

Automative

Global Peptide Cancer Vaccine Market Research Report 2025

Published Date: August 2025

Report Code: QYRE-Auto-1L12300

Global Peptide Cancer Vaccine Market Size Manufacturers Supply Chain Sales Channel and Clients 2022 2028

BUY CHAPTERS

Global Peptide Cancer Vaccine Market Research Report 2025

Code: QYRE-Auto-1L12300

Report

August 2025

Pages:81

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Boston Biomedical

Ultimovacs

BrightPath Biotherapeutics

TapImmune

Immatics

Sellas

Imugene

VAXON Biotech

Generex Biotechnology

ISA Pharmaceuticals

OncoTherapy Science

Peptide Cancer Vaccine Market Size

The global market for Peptide Cancer Vaccine was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of 19.8% during the forecast period.

Peptide Cancer Vaccine Market

Peptide cancer vaccines are innovative immunotherapy products designed based on specific tumor-associated antigen peptides. By delivering selected peptide sequences into patients, these vaccines activate T cells within the immune system to recognize and attack tumor cells, achieving targeted anti-cancer effects. Compared to traditional therapies, peptide vaccines offer strong specificity, low side effects, and ease of production, and can be combined with other immunotherapies or chemotherapies to enhance treatment efficacy. With advancements in molecular biology and immunology, peptide cancer vaccines demonstrate broad potential in personalized treatments and applications across multiple tumor types, marking a significant breakthrough and emerging trend in the field of tumor immunotherapy.

The global increase in cancer patient populations drives strong demand for effective, safe, and personalized treatment solutions. Annual reports from leading biopharmaceutical companies highlight intensified investments in peptide cancer vaccine R&D, fostering technological innovation and clinical trial progress to strengthen market competitiveness. Governments worldwide support innovative medical technologies through policies and funding, accelerating peptide vaccine development and commercialization. The strong specificity and combinational therapy potential of peptide vaccines meet diverse needs across cancer types and patient populations, especially demonstrating value in refractory and recurrent tumors. The widespread adoption of precision medicine concepts and advances in bioinformatics-aided design further enhance R&D efficiency and market penetration.

The peptide cancer vaccine market faces challenges including high technical complexity, lengthy development cycles, and stringent clinical validation requirements. Regulatory policies and approval processes vary across countries and regions, increasing difficulty and cost for international market expansion. Market competition intensifies amid coexistence of traditional therapies and multiple emerging immunotherapies, requiring continuous innovation to maintain leadership. High R&D investment and production costs limit participation of some small and medium enterprises and broader product accessibility. Uncertainties in efficacy and safety necessitate strengthened clinical data support and risk management to ensure market acceptance and long-term competitiveness.

Future downstream demand for peptide cancer vaccines will exhibit personalization, diversification, and integration. Major comprehensive hospitals and oncology centers serve as primary markets, emphasizing treatment efficacy, safety, and synergy with existing therapies. Patient demand for precise and low-side-effect innovative treatments fuels rapid growth in personalized peptide vaccine customization and combination therapies. Advances in companion diagnostics and biomarkers enable more precise patient matching, maximizing therapeutic outcomes. Suppliers must continually enhance R&D capabilities and service quality to meet complex and evolving clinical needs and regulatory environments.

This report aims to provide a comprehensive presentation of the global market for Peptide Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Cancer Vaccine.

The Peptide Cancer Vaccine market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peptide Cancer Vaccine market comprehensively. Regional market sizes, concerning products by Pipeline, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Peptide Cancer Vaccine companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Pipeline, by Application, and by regions.

Market Segmentation

Scope of Peptide Cancer Vaccine Market Report

Report Metric	Details
Report Name	Peptide Cancer Vaccine Market
CAGR	19.8%
Segment by Pipeline	ITK-1 GRN-1201 TPIV200 TPIV110 UV1 Galinpepimut-S TARP 27-35 HER-Vaxx Vx-001 Others
Segment by Application	Breast Cancer Lung Cancer Melanoma Prostate Cancer Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals, OncoTherapy Science
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Pipeline, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide Cancer Vaccine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Pipeline, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Peptide Cancer Vaccine Market report?

Ans: The main players in the Peptide Cancer Vaccine Market are Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals, OncoTherapy Science

What are the Application segmentation covered in the Peptide Cancer Vaccine Market report?

Ans: The Applications covered in the Peptide Cancer Vaccine Market report are Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Pipeline

1.2.1 Global Peptide Cancer Vaccine Market Size Growth Rate by Pipeline: 2020 VS 2024 VS 2031

1.2.2 ITK-1

1.2.3 GRN-1201

1.2.4 TPIV200

1.2.5 TPIV110

1.2.6 UV1

1.2.7 Galinpepimut-S

1.2.8 TARP 27-35

1.2.9 HER-Vaxx

1.2.10 Vx-001

1.3 Market by Application

1.3.1 Global Peptide Cancer Vaccine Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Breast Cancer

1.3.3 Lung Cancer

1.3.4 Melanoma

1.3.5 Prostate Cancer

1.3.6 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Peptide Cancer Vaccine Market Perspective (2020-2031)

2.2 Global Peptide Cancer Vaccine Growth Trends by Region

2.2.1 Global Peptide Cancer Vaccine Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Peptide Cancer Vaccine Historic Market Size by Region (2020-2025)

2.2.3 Peptide Cancer Vaccine Forecasted Market Size by Region (2026-2031)

2.3 Peptide Cancer Vaccine Market Dynamics

2.3.1 Peptide Cancer Vaccine Industry Trends

2.3.2 Peptide Cancer Vaccine Market Drivers

2.3.3 Peptide Cancer Vaccine Market Challenges

2.3.4 Peptide Cancer Vaccine Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Peptide Cancer Vaccine Players by Revenue

3.1.1 Global Top Peptide Cancer Vaccine Players by Revenue (2020-2025)

3.1.2 Global Peptide Cancer Vaccine Revenue Market Share by Players (2020-2025)

3.2 Global Top Peptide Cancer Vaccine Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Peptide Cancer Vaccine Revenue

3.4 Global Peptide Cancer Vaccine Market Concentration Ratio

3.4.1 Global Peptide Cancer Vaccine Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Peptide Cancer Vaccine Revenue in 2024

3.5 Global Key Players of Peptide Cancer Vaccine Head office and Area Served

3.6 Global Key Players of Peptide Cancer Vaccine, Product and Application

3.7 Global Key Players of Peptide Cancer Vaccine, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Peptide Cancer Vaccine Breakdown Data by Pipeline

4.1 Global Peptide Cancer Vaccine Historic Market Size by Pipeline (2020-2025)

4.2 Global Peptide Cancer Vaccine Forecasted Market Size by Pipeline (2026-2031)

5 Peptide Cancer Vaccine Breakdown Data by Application

5.1 Global Peptide Cancer Vaccine Historic Market Size by Application (2020-2025)

5.2 Global Peptide Cancer Vaccine Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Peptide Cancer Vaccine Market Size (2020-2031)

6.2 North America Peptide Cancer Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Peptide Cancer Vaccine Market Size by Country (2020-2025)

6.4 North America Peptide Cancer Vaccine Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Peptide Cancer Vaccine Market Size (2020-2031)

7.2 Europe Peptide Cancer Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Peptide Cancer Vaccine Market Size by Country (2020-2025)

7.4 Europe Peptide Cancer Vaccine Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Peptide Cancer Vaccine Market Size (2020-2031)

8.2 Asia-Pacific Peptide Cancer Vaccine Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Peptide Cancer Vaccine Market Size by Region (2020-2025)

8.4 Asia-Pacific Peptide Cancer Vaccine Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Peptide Cancer Vaccine Market Size (2020-2031)

9.2 Latin America Peptide Cancer Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Peptide Cancer Vaccine Market Size by Country (2020-2025)

9.4 Latin America Peptide Cancer Vaccine Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Peptide Cancer Vaccine Market Size (2020-2031)

10.2 Middle East & Africa Peptide Cancer Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Peptide Cancer Vaccine Market Size by Country (2020-2025)

10.4 Middle East & Africa Peptide Cancer Vaccine Market Size by Country (2026-2031)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Boston Biomedical

11.1.1 Boston Biomedical Company Details

11.1.2 Boston Biomedical Business Overview

11.1.3 Boston Biomedical Peptide Cancer Vaccine Introduction

11.1.4 Boston Biomedical Revenue in Peptide Cancer Vaccine Business (2020-2025)

11.1.5 Boston Biomedical Recent Development

11.2 Ultimovacs

11.2.1 Ultimovacs Company Details

11.2.2 Ultimovacs Business Overview

11.2.3 Ultimovacs Peptide Cancer Vaccine Introduction

11.2.4 Ultimovacs Revenue in Peptide Cancer Vaccine Business (2020-2025)

11.2.5 Ultimovacs Recent Development

11.3 BrightPath Biotherapeutics

11.3.1 BrightPath Biotherapeutics Company Details

11.3.2 BrightPath Biotherapeutics Business Overview

11.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Introduction

11.3.4 BrightPath Biotherapeutics Revenue in Peptide Cancer Vaccine Business (2020-2025)

11.3.5 BrightPath Biotherapeutics Recent Development

11.4 TapImmune

11.4.1 TapImmune Company Details

11.4.2 TapImmune Business Overview

11.4.3 TapImmune Peptide Cancer Vaccine Introduction

11.4.4 TapImmune Revenue in Peptide Cancer Vaccine Business (2020-2025)

11.4.5 TapImmune Recent Development

11.5 Immatics

11.5.1 Immatics Company Details

11.5.2 Immatics Business Overview

11.5.3 Immatics Peptide Cancer Vaccine Introduction

11.5.4 Immatics Revenue in Peptide Cancer Vaccine Business (2020-2025)

11.5.5 Immatics Recent Development

11.6 Sellas

11.6.1 Sellas Company Details

11.6.2 Sellas Business Overview

11.6.3 Sellas Peptide Cancer Vaccine Introduction

11.6.4 Sellas Revenue in Peptide Cancer Vaccine Business (2020-2025)

11.6.5 Sellas Recent Development

11.7 Imugene

11.7.1 Imugene Company Details

11.7.2 Imugene Business Overview

11.7.3 Imugene Peptide Cancer Vaccine Introduction

11.7.4 Imugene Revenue in Peptide Cancer Vaccine Business (2020-2025)

11.7.5 Imugene Recent Development

11.8 VAXON Biotech

11.8.1 VAXON Biotech Company Details

11.8.2 VAXON Biotech Business Overview

11.8.3 VAXON Biotech Peptide Cancer Vaccine Introduction

11.8.4 VAXON Biotech Revenue in Peptide Cancer Vaccine Business (2020-2025)

11.8.5 VAXON Biotech Recent Development

11.9 Generex Biotechnology

11.9.1 Generex Biotechnology Company Details

11.9.2 Generex Biotechnology Business Overview

11.9.3 Generex Biotechnology Peptide Cancer Vaccine Introduction

11.9.4 Generex Biotechnology Revenue in Peptide Cancer Vaccine Business (2020-2025)

11.9.5 Generex Biotechnology Recent Development

11.10 ISA Pharmaceuticals

11.10.1 ISA Pharmaceuticals Company Details

11.10.2 ISA Pharmaceuticals Business Overview

11.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Introduction

11.10.4 ISA Pharmaceuticals Revenue in Peptide Cancer Vaccine Business (2020-2025)

11.10.5 ISA Pharmaceuticals Recent Development

11.11 OncoTherapy Science

11.11.1 OncoTherapy Science Company Details

11.11.2 OncoTherapy Science Business Overview

11.11.3 OncoTherapy Science Peptide Cancer Vaccine Introduction

11.11.4 OncoTherapy Science Revenue in Peptide Cancer Vaccine Business (2020-2025)

11.11.5 OncoTherapy Science Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Boston Biomedical

Ultimovacs

BrightPath Biotherapeutics

TapImmune

Immatics

Sellas

Imugene

VAXON Biotech

Generex Biotechnology

ISA Pharmaceuticals

OncoTherapy Science

List of Tables

Table 1. Global Peptide Cancer Vaccine Market Size Growth Rate by Pipeline (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of ITK-1

Table 3. Key Players of GRN-1201

Table 4. Key Players of TPIV200

Table 5. Key Players of TPIV110

Table 6. Key Players of UV1

Table 7. Key Players of Galinpepimut-S

Table 8. Key Players of TARP 27-35

Table 9. Global Peptide Cancer Vaccine Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 10. Global Peptide Cancer Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 11. Global Peptide Cancer Vaccine Market Size by Region (2020-2025) & (US$ Million)

Table 12. Global Peptide Cancer Vaccine Market Share by Region (2020-2025)

Table 13. Global Peptide Cancer Vaccine Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 14. Global Peptide Cancer Vaccine Market Share by Region (2026-2031)

Table 15. Peptide Cancer Vaccine Market Trends

Table 16. Peptide Cancer Vaccine Market Drivers

Table 17. Peptide Cancer Vaccine Market Challenges

Table 18. Peptide Cancer Vaccine Market Restraints

Table 19. Global Peptide Cancer Vaccine Revenue by Players (2020-2025) & (US$ Million)

Table 20. Global Peptide Cancer Vaccine Market Share by Players (2020-2025)

Table 21. Global Top Peptide Cancer Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Cancer Vaccine as of 2024)

Table 22. Ranking of Global Top Peptide Cancer Vaccine Companies by Revenue (US$ Million) in 2024

Table 23. Global 5 Largest Players Market Share by Peptide Cancer Vaccine Revenue (CR5 and HHI) & (2020-2025)

Table 24. Global Key Players of Peptide Cancer Vaccine, Headquarters and Area Served

Table 25. Global Key Players of Peptide Cancer Vaccine, Product and Application

Table 26. Global Key Players of Peptide Cancer Vaccine, Date of Enter into This Industry

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Peptide Cancer Vaccine Market Size by Pipeline (2020-2025) & (US$ Million)

Table 29. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2020-2025)

Table 30. Global Peptide Cancer Vaccine Forecasted Market Size by Pipeline (2026-2031) & (US$ Million)

Table 31. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2026-2031)

Table 32. Global Peptide Cancer Vaccine Market Size by Application (2020-2025) & (US$ Million)

Table 33. Global Peptide Cancer Vaccine Revenue Market Share by Application (2020-2025)

Table 34. Global Peptide Cancer Vaccine Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 35. Global Peptide Cancer Vaccine Revenue Market Share by Application (2026-2031)

Table 36. North America Peptide Cancer Vaccine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. North America Peptide Cancer Vaccine Market Size by Country (2020-2025) & (US$ Million)

Table 38. North America Peptide Cancer Vaccine Market Size by Country (2026-2031) & (US$ Million)

Table 39. Europe Peptide Cancer Vaccine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 40. Europe Peptide Cancer Vaccine Market Size by Country (2020-2025) & (US$ Million)

Table 41. Europe Peptide Cancer Vaccine Market Size by Country (2026-2031) & (US$ Million)

Table 42. Asia-Pacific Peptide Cancer Vaccine Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 43. Asia-Pacific Peptide Cancer Vaccine Market Size by Region (2020-2025) & (US$ Million)

Table 44. Asia-Pacific Peptide Cancer Vaccine Market Size by Region (2026-2031) & (US$ Million)

Table 45. Latin America Peptide Cancer Vaccine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Latin America Peptide Cancer Vaccine Market Size by Country (2020-2025) & (US$ Million)

Table 47. Latin America Peptide Cancer Vaccine Market Size by Country (2026-2031) & (US$ Million)

Table 48. Middle East & Africa Peptide Cancer Vaccine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 49. Middle East & Africa Peptide Cancer Vaccine Market Size by Country (2020-2025) & (US$ Million)

Table 50. Middle East & Africa Peptide Cancer Vaccine Market Size by Country (2026-2031) & (US$ Million)

Table 51. Boston Biomedical Company Details

Table 52. Boston Biomedical Business Overview

Table 53. Boston Biomedical Peptide Cancer Vaccine Product

Table 54. Boston Biomedical Revenue in Peptide Cancer Vaccine Business (2020-2025) & (US$ Million)

Table 55. Boston Biomedical Recent Development

Table 56. Ultimovacs Company Details

Table 57. Ultimovacs Business Overview

Table 58. Ultimovacs Peptide Cancer Vaccine Product

Table 59. Ultimovacs Revenue in Peptide Cancer Vaccine Business (2020-2025) & (US$ Million)

Table 60. Ultimovacs Recent Development

Table 61. BrightPath Biotherapeutics Company Details

Table 62. BrightPath Biotherapeutics Business Overview

Table 63. BrightPath Biotherapeutics Peptide Cancer Vaccine Product

Table 64. BrightPath Biotherapeutics Revenue in Peptide Cancer Vaccine Business (2020-2025) & (US$ Million)

Table 65. BrightPath Biotherapeutics Recent Development

Table 66. TapImmune Company Details

Table 67. TapImmune Business Overview

Table 68. TapImmune Peptide Cancer Vaccine Product

Table 69. TapImmune Revenue in Peptide Cancer Vaccine Business (2020-2025) & (US$ Million)

Table 70. TapImmune Recent Development

Table 71. Immatics Company Details

Table 72. Immatics Business Overview

Table 73. Immatics Peptide Cancer Vaccine Product

Table 74. Immatics Revenue in Peptide Cancer Vaccine Business (2020-2025) & (US$ Million)

Table 75. Immatics Recent Development

Table 76. Sellas Company Details

Table 77. Sellas Business Overview

Table 78. Sellas Peptide Cancer Vaccine Product

Table 79. Sellas Revenue in Peptide Cancer Vaccine Business (2020-2025) & (US$ Million)

Table 80. Sellas Recent Development

Table 81. Imugene Company Details

Table 82. Imugene Business Overview

Table 83. Imugene Peptide Cancer Vaccine Product

Table 84. Imugene Revenue in Peptide Cancer Vaccine Business (2020-2025) & (US$ Million)

Table 85. Imugene Recent Development

Table 86. VAXON Biotech Company Details

Table 87. VAXON Biotech Business Overview

Table 88. VAXON Biotech Peptide Cancer Vaccine Product

Table 89. VAXON Biotech Revenue in Peptide Cancer Vaccine Business (2020-2025) & (US$ Million)

Table 90. VAXON Biotech Recent Development

Table 91. Generex Biotechnology Company Details

Table 92. Generex Biotechnology Business Overview

Table 93. Generex Biotechnology Peptide Cancer Vaccine Product

Table 94. Generex Biotechnology Revenue in Peptide Cancer Vaccine Business (2020-2025) & (US$ Million)

Table 95. Generex Biotechnology Recent Development

Table 96. ISA Pharmaceuticals Company Details

Table 97. ISA Pharmaceuticals Business Overview

Table 98. ISA Pharmaceuticals Peptide Cancer Vaccine Product

Table 99. ISA Pharmaceuticals Revenue in Peptide Cancer Vaccine Business (2020-2025) & (US$ Million)

Table 100. ISA Pharmaceuticals Recent Development

Table 101. OncoTherapy Science Company Details

Table 102. OncoTherapy Science Business Overview

Table 103. OncoTherapy Science Peptide Cancer Vaccine Product

Table 104. OncoTherapy Science Revenue in Peptide Cancer Vaccine Business (2020-2025) & (US$ Million)

Table 105. OncoTherapy Science Recent Development

Table 106. Research Programs/Design for This Report

Table 107. Key Data Information from Secondary Sources

Table 108. Key Data Information from Primary Sources

Table 109. Authors List of This Report

List of Figures

Figure 1. Peptide Cancer Vaccine Picture

Figure 2. Global Peptide Cancer Vaccine Market Size Comparison by Pipeline (2020-2031) & (US$ Million)

Figure 3. Global Peptide Cancer Vaccine Market Share by Pipeline: 2024 VS 2031

Figure 4. ITK-1 Features

Figure 5. GRN-1201 Features

Figure 6. TPIV200 Features

Figure 7. TPIV110 Features

Figure 8. UV1 Features

Figure 9. Galinpepimut-S Features

Figure 10. TARP 27-35 Features

Figure 11. HER-Vaxx Features

Figure 12. Vx-001 Features

Figure 13. Global Peptide Cancer Vaccine Market Size by Application (2020-2031) & (US$ Million)

Figure 14. Global Peptide Cancer Vaccine Market Share by Application: 2024 VS 2031

Figure 15. Breast Cancer Case Studies

Figure 16. Lung Cancer Case Studies

Figure 17. Melanoma Case Studies

Figure 18. Prostate Cancer Case Studies

Figure 19. Others Case Studies

Figure 20. Peptide Cancer Vaccine Report Years Considered

Figure 21. Global Peptide Cancer Vaccine Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 22. Global Peptide Cancer Vaccine Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 23. Global Peptide Cancer Vaccine Market Share by Region: 2024 VS 2031

Figure 24. Global Peptide Cancer Vaccine Market Share by Players in 2024

Figure 25. Global Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 26. The Top 10 and 5 Players Market Share by Peptide Cancer Vaccine Revenue in 2024

Figure 27. North America Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. North America Peptide Cancer Vaccine Market Share by Country (2020-2031)

Figure 29. United States Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Canada Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Europe Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Europe Peptide Cancer Vaccine Market Share by Country (2020-2031)

Figure 33. Germany Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. France Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. U.K. Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Italy Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Russia Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Ireland Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Asia-Pacific Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Asia-Pacific Peptide Cancer Vaccine Market Share by Region (2020-2031)

Figure 41. China Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Japan Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. South Korea Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Southeast Asia Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. India Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Australia & New Zealand Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Latin America Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Latin America Peptide Cancer Vaccine Market Share by Country (2020-2031)

Figure 49. Mexico Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Brazil Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Middle East & Africa Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. Middle East & Africa Peptide Cancer Vaccine Market Share by Country (2020-2031)

Figure 53. Israel Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 54. Saudi Arabia Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 55. UAE Peptide Cancer Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 56. Boston Biomedical Revenue Growth Rate in Peptide Cancer Vaccine Business (2020-2025)

Figure 57. Ultimovacs Revenue Growth Rate in Peptide Cancer Vaccine Business (2020-2025)

Figure 58. BrightPath Biotherapeutics Revenue Growth Rate in Peptide Cancer Vaccine Business (2020-2025)

Figure 59. TapImmune Revenue Growth Rate in Peptide Cancer Vaccine Business (2020-2025)

Figure 60. Immatics Revenue Growth Rate in Peptide Cancer Vaccine Business (2020-2025)

Figure 61. Sellas Revenue Growth Rate in Peptide Cancer Vaccine Business (2020-2025)

Figure 62. Imugene Revenue Growth Rate in Peptide Cancer Vaccine Business (2020-2025)

Figure 63. VAXON Biotech Revenue Growth Rate in Peptide Cancer Vaccine Business (2020-2025)

Figure 64. Generex Biotechnology Revenue Growth Rate in Peptide Cancer Vaccine Business (2020-2025)

Figure 65. ISA Pharmaceuticals Revenue Growth Rate in Peptide Cancer Vaccine Business (2020-2025)

Figure 66. OncoTherapy Science Revenue Growth Rate in Peptide Cancer Vaccine Business (2020-2025)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Peptide Vaccine for Tumor Market Research Report 2024

Global Peptide Based Cancer Therapeutics Market Research Report 2024

Global Polypeptide Vaccine Market Research Report 2024

Peptide Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Tumor Targeting Peptides Market Research Report 2024

Global Adjuvant Peptide Market Research Report 2024

Synthetic Peptide Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Peptide Therapy Market Research Report 2025

Peptide Based Drug Delivery System Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Tumour cell Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Therapeutic Cancer Vaccines Market Research Report 2024

Global Cancer Immunotherapies Market Insights Forecast to 2030

Recombinant Peptide Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Molecular Cancer Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Peptide based Generics Market Research Report 2024

Global Cancer Immunotherapy Market Insights Forecast to 2030

Global Emerging Cancer Vaccines Market Insights Forecast to 2030

Global Immuno oncology Clinical Trials Market Research Report 2024

Prostate Cancer Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions